Alere Announces Preliminary Results Of Voting At Annual Meeting
WALTHAM, Mass., Aug. 7, 2013
WALTHAM, Mass., Aug. 7, 2013 /PRNewswire/ --Alere Inc. (NYSE: ALR) (the
"Company" or "Alere") today announced that, based on a preliminary count of
votes cast at the Company's 2013 Annual Meeting of Stockholders held today,
stockholders have elected all four of the Company's director nominees, Hakan
Bjorklund, Stephen MacMillan, Brian Markison and Sir Thomas McKillop.
Alere issued the following statement:
"Alere's Board and management team appreciate the feedback we have received
from our stockholders, and we extend our gratitude for their support of our
independent director nominees. Our plan to improve organic revenue growth,
drive higher operating margins and reduce leverage has been recognized.
While we are pleased with our progress to date, this process has only
further sharpened our commitment to delivering strong results.
"We look forward to benefitting from the unique operational experience and
fresh perspectives of our new board members and building on our positive
momentum as we continue to work to enhance stockholder value. We also look
forward to our Board acting on the recommendation to appoint Gregg Powers,
who our nominating committee believes can help guide our strategy and serve
as another independent voice for stockholders on the Board."
The preliminary voting also indicated that stockholders approved all of the
other proposals submitted for a vote at the Annual Meeting.
The meeting was adjourned to 12:30 p.m. on August 19, 2013 at The Emerging
Enterprise Center at Foley Hoag LLP located at 1000 Winter Street, Suite 4000,
Waltham, Massachusetts 02451, solely to receive the final report of IVS
Associates, Inc., the independent inspector of elections.
By developing new capabilities in near-patient diagnosis, monitoring and
health information technology, Alere enables individuals to take charge of
improving their health and quality of life at home. Alere's global leading
products and services, as well as its new product development efforts, focus
on cardiology, infectious disease, toxicology and diabetes. Alere is
headquartered in Waltham, Massachusetts. For more information regarding Alere
please visit www.alere.com.
This press release contains forward-looking statements within the meaning of
the federal securities laws, including statements regarding the outcome of the
vote on each matter. These statements reflect our current views with respect
to future events and are based on management's current assumptions and
information currently available. Actual results may differ materially due to
numerous factors including, without limitation, the independent inspector's
final tabulation of voting results. We undertake no obligation to update any
forward-looking statements contained herein.
SOURCE Alere Inc.
Contact: Kelly Sullivan / Annabelle Rinehart / Dan Moore, Joele Frank,
Wilkinson Brimmer, Katcher, 212-355-4449
Press spacebar to pause and continue. Press esc to stop.